The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...

A new study highlights a significant medical concern for individuals suffering from psoriasis, revealing that even when skin ...

In a country where chronic skin diseases affect millions, one institution is rewriting the rulebook. Kayakalp Global, based ...

Clearance of ASC50 paves the way for a Phase I trial in patients with mild-to-moderate plaque psoriasis.

The FDA approved a supplemental new drug application for roflumilast topical foam 0.3% for the treatment of plaque psoriasis ...

The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and ...

Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...

Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for a Phase I trial for ASC50 for the ...

The study reveals that patients with both T2D and psoriasis face a significantly elevated risk of developing renal conditions ...

Moderate and severe psoriasis requires treatment of not only your skin ... The appearance of a new skin lesion as a result of a skin injury is known as the Koebner phenomenon.

While previous treatment approaches have mainly focused ... is associated with reduced psoriasis severity, new research ... A Light-Activated Drug to Fight Psoriasis Feb. 3, 2025 — Psoriasis ...

In calling for more clinical testing of vaccines in younger people and those who face a low risk of severe disease from Covid ...